The identification of PI3K, MAPK and NFκB through IPA analysis as central nodes of the Rb-dependent hypoxia signal in the neurological disease network leads to the intriguing possibilities of new drug targets for late stage prostate cancer (Figure 4C). The gene discussed is RB1; the disease is prostate carcinoma.